SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study
Despite guideline recommendations, SGLT2 inhibitors and GLP-1RAs are prescribed to only a minority of patients with newly diagnosed T2DM, even among those with clear indications. Efforts to improve guideline-adherent care in primary care settings are needed.
Authors
- Omayma Alshaarawy (ORCID: https://orcid.org/0000-0002-5968-0245)
- Frank Müller (ORCID: https://orcid.org/0000-0002-9496-9423)
- Harland Holman (ORCID: https://orcid.org/0000-0003-3835-9193)
- Michael J. Bouthillier
- Hend Azhary
Institutions
- Grand Rapids Community College (US)
- Northwell Health (US)
- Universitätsmedizin Göttingen (DE)
- Michigan State University (US)
Publication Details
- Journal
- Journal of Diabetes Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/jdr/6656982
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29